| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c7ad58d3c0b071069a8ee0cb8c8ba2e8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-686
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-6823
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-4839 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H40-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-0537
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-4875 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H20-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04 |
| filingDate |
2019-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81d0b0bffd4cb911a4de28e74700cd12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa612ae3f63570baa1641950529c0ccc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eef525c59196fe0ad89a1db9e3b49104
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_adc556ecc5ddf1c6590fff27a08effe0 |
| publicationDate |
2020-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3740236-A1 |
| titleOfInvention |
Assistance in the treatment of cardiac insufficiency |
| abstract |
The present invention relates to the treatment of cardiac insufficiency. A sensor for measuring the tissue fluid content in the region of the rib cage is implanted in a person suffering from cardiac insufficiency. If the tissue fluid content does not get back to normal within a defined period of time and under treatment with the available standard therapy, treatment with a V1a/V2 vasopressin receptor antagonist is recommended. Dosage of the V1a/V2 vasopressin receptor antagonist and duration of the treatment with the V1a/V2 vasopressin receptor antagonist can be determined on the basis of the acquired sensor data. |
| priorityDate |
2018-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |